drugset / Trial / NCT03656094
Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors
RandomizedParallel-groupQuadruple-blindTreatment
Summary
After progression to previous PD-1/L1 inhibitors (pembrolizumab, nivolumab, or atezolizumab), physicians' choice chemotherapy plus pembolizumab (or placebo) will be administered (3 weeks per cycle) until disease progression or unacceptable toxicity.
Timeline
- Start
- 2018-11-01
- Primary completion
- 2020-11-01
- Completion
- 2021-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |
| Background | Docetaxel | Small molecule | — | — |
| Background | Pemetrexed | Small molecule | — | — |
| Background | Vinorelbine | Small molecule | — | — |